NanoTemper Technologies

NanoTemper Technologies, founded in 2008 and headquartered in Munich, Germany, is a private provider of innovative biophysical analysis instruments. The company's product portfolio, including Prometheus, Dianthus, Monolith, and Andromeda, addresses critical bottlenecks in drug discovery by enabling label-free, in-solution analysis of protein stability and binding affinities with minimal sample consumption. Its tools are used by top biopharmaceutical companies and academic institutions to characterize complex therapeutics like biologics, PROTACs, and intrinsically disordered proteins. As a founder-owned entity, NanoTemper focuses on empowering scientists with reliable, high-quality data to accelerate therapeutic development.

Suite of label-free, in-solution biophysical analysis technologies including MicroScale Thermophoresis (MST), nano-Differential Scanning Fluorimetry (nanoDSF), Dynamic Light Scattering (DLS), and Spectral Shift detection for measuring protein stability, binding affinities, and expression quality.

NanoTemper competes in the biophysical characterization market against major players like Malvern Panalytical (DLS, SPR), Sartorius (BLI, Octet), and TA Instruments/Waters (ITC, DSC). Its competitive advantage lies in its specialized, orthogonal technologies (MST, Spectral Shift) that solve specific, challenging problems where conventional methods fail, and in its strong reputation for ease-of-use and low sample consumption.